277 related articles for article (PubMed ID: 33219704)
1. Management of non-transfusion-dependent β-thalassemia (NTDT): The next 5 years.
Musallam KM; Rivella S; Taher AT
Am J Hematol; 2021 Mar; 96(3):E57-E59. PubMed ID: 33219704
[No Abstract] [Full Text] [Related]
2. SARS-CoV-2 infection in patients with β-thalassemia: Experience from Lebanon.
Bou-Fakhredin R; Daadaa H; Koussa S; Abou Nasr T; Noun P; Taher AT
Am J Hematol; 2021 Aug; 96(8):E285-E288. PubMed ID: 33914955
[No Abstract] [Full Text] [Related]
3. How I treat non-transfusion-dependent β-thalassemia.
Saliba AN; Musallam KM; Taher AT
Blood; 2023 Sep; 142(11):949-960. PubMed ID: 37478396
[TBL] [Abstract][Full Text] [Related]
4. Treating iron overload in patients with non-transfusion-dependent thalassemia.
Taher AT; Viprakasit V; Musallam KM; Cappellini MD
Am J Hematol; 2013 May; 88(5):409-15. PubMed ID: 23475638
[TBL] [Abstract][Full Text] [Related]
5. β-Thalassemias.
Taher AT; Musallam KM; Cappellini MD
N Engl J Med; 2021 Feb; 384(8):727-743. PubMed ID: 33626255
[No Abstract] [Full Text] [Related]
6. Ineffective Erythropoiesis in β-Thalassaemia: Key Steps and Therapeutic Options by Drugs.
Longo F; Piolatto A; Ferrero GB; Piga A
Int J Mol Sci; 2021 Jul; 22(13):. PubMed ID: 34281283
[TBL] [Abstract][Full Text] [Related]
7. β-Thalassemia: evolving treatment options beyond transfusion and iron chelation.
Langer AL; Esrick EB
Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):600-606. PubMed ID: 34889443
[TBL] [Abstract][Full Text] [Related]
8. Profile of Luspatercept in the Treatment of Anemia in Adults with Non-Transfusion-Dependent β-Thalassemia (NTDT): Design, Development and Potential Place in Therapy.
Musallam KM; Taher AT; Kattamis A; Kuo KHM; Sheth S; Cappellini MD
Drug Des Devel Ther; 2023; 17():1583-1591. PubMed ID: 37255740
[TBL] [Abstract][Full Text] [Related]
9. Oral iron chelation therapy for thalassaemia: an uncertain scene.
Pippard MJ; Weatherall DJ
Br J Haematol; 2000 Oct; 111(1):2-5. PubMed ID: 11091177
[No Abstract] [Full Text] [Related]
10. New therapeutic targets in transfusion-dependent and -independent thalassemia.
Cappellini MD; Motta I
Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):278-283. PubMed ID: 29222267
[TBL] [Abstract][Full Text] [Related]
11. Drug safety in thalassemia: lessons from the present and directions for the future.
Grech L; Sultana J; Borg K; Borg J
Expert Opin Drug Saf; 2021 Aug; 20(8):937-947. PubMed ID: 33877003
[No Abstract] [Full Text] [Related]
12. [Current management of thalassemia intermedia].
Thuret I
Transfus Clin Biol; 2014 Nov; 21(4-5):143-9. PubMed ID: 25282488
[TBL] [Abstract][Full Text] [Related]
13. New partners for Luspatercept in β-thalassemia.
Vinchi F
Am J Hematol; 2024 Jul; 99(7):1217-1219. PubMed ID: 38752378
[No Abstract] [Full Text] [Related]
14. Luspatercept to treat β-thalassemia.
Pilo F; Angelucci E
Drugs Today (Barc); 2020 Jul; 56(7):447-458. PubMed ID: 32648855
[TBL] [Abstract][Full Text] [Related]
15. Liver iron concentrations and urinary hepcidin in beta-thalassemia.
Origa R; Galanello R; Ganz T; Giagu N; Maccioni L; Faa G; Nemeth E
Haematologica; 2007 May; 92(5):583-8. PubMed ID: 17488680
[TBL] [Abstract][Full Text] [Related]
16. Iron chelation therapy for non-transfusion-dependent thalassemia (NTDT): a status quo.
Taher AT; Musallam KM; Viprakasit V; Porter JB; Cappellini MD
Blood Cells Mol Dis; 2014; 52(2-3):88-90. PubMed ID: 24041597
[No Abstract] [Full Text] [Related]
17. Combination of a TGF-β ligand trap (RAP-GRL) and TMPRSS6-ASO is superior for correcting β-thalassemia.
Guerra A; Hamilton N; Rivera A; Demsko P; Guo S; Rivella S
Am J Hematol; 2024 Jul; 99(7):1300-1312. PubMed ID: 38659383
[TBL] [Abstract][Full Text] [Related]
18. Clinical monitoring and management of complications related to chelation therapy in patients with β-thalassemia.
Saliba AN; El Rassi F; Taher AT
Expert Rev Hematol; 2016; 9(2):151-68. PubMed ID: 26613264
[TBL] [Abstract][Full Text] [Related]
19. A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia.
Cappellini MD; Viprakasit V; Taher AT; Georgiev P; Kuo KHM; Coates T; Voskaridou E; Liew HK; Pazgal-Kobrowski I; Forni GL; Perrotta S; Khelif A; Lal A; Kattamis A; Vlachaki E; Origa R; Aydinok Y; Bejaoui M; Ho PJ; Chew LP; Bee PC; Lim SM; Lu MY; Tantiworawit A; Ganeva P; Gercheva L; Shah F; Neufeld EJ; Thompson A; Laadem A; Shetty JK; Zou J; Zhang J; Miteva D; Zinger T; Linde PG; Sherman ML; Hermine O; Porter J; Piga A;
N Engl J Med; 2020 Mar; 382(13):1219-1231. PubMed ID: 32212518
[TBL] [Abstract][Full Text] [Related]
20. Acute liver injury after SARS-CoV-2 vaccination and luspatercept administration in a patient with β-thalassemia.
Leoni S; Bou-Fakhredin R; Granata F; Cassinerio E; Maggioni M; Fracanzani AL; Cappellini MD; Motta I
Ann Hematol; 2024 Mar; 103(3):1025-1026. PubMed ID: 38170241
[No Abstract] [Full Text] [Related]
[Next] [New Search]